Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
1.420
-0.080 (-5.33%)
At close: Dec 30, 2024, 4:00 PM
1.440
+0.020 (1.41%)
After-hours: Dec 30, 2024, 5:51 PM EST
Company Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.
It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Mersana Therapeutics, Inc.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Martin Huber |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts 02139 United States | |
| Phone | 617 498 0020 |
| Website | mersana.com |
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L106 |
| ISIN Number | US59045L1061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Huber | Chief Executive Officer |
| Brian DeSchuytner | Chief Financial Officer |
| Brian DeSchuytner | Chief Operating Officer |
| Jason Fredette | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | SCHEDULE 13G/A | Filing |
| Dec 23, 2024 | SCHEDULE 13G/A | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 144 | Filing |
| Oct 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |